Biotech Week articles from December 2002

Biotech Week archives from December 2002

New treatment strategy shows early promise.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- A preliminary study reports that enhancing the body's innate immunity can improve symptoms of Crohn disease in 80% of patients with moderate to severe forms of the debilitating, inflammatory...

FDA approves new female sterilization device.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration has approved a small metallic implant that is placed into the fallopian tubes of women who wish to be permanently sterilized. Unlike other currently available...

Combination therapy no more effective than single therapy to lower mortality.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- For patients who suffered a heart attack, using the combination therapy of the fibrinolytic ("clot-busting") drug reteplase and the platelet blocking drug abciximab did not reduce their risk of death...

Microarray technology provides insight into potential vaccine agents.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Using DNA microarray techniques, over 100 proteins having unknown functions were discovered during interactions between Neisseria meningitidis and...

Drotrecogin alfa drug sustains long-term survival.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- by Lynn Yoffee, senior medical writer - A genetically engineered drug - drotrecogin alfa (Xigris) - already proven to help patients survive the acute phase of severe sepsis also helps them remain alive...

Study: Tumor regression occurs after injection of DNA complex.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- In a scientific article published this month, a group of research scientists with Genzyme Molecular Oncology (GZMO) report that immune-stimulating complexes made up of lipid and plasmid DNA produced...

Cardiomyocytes can be extensively generated from embryonic cells.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Embryonic stem cells could be a rich source of functional heart cells, researchers in the United States argue. "Cell replacement therapy is a promising...

FDA approves rapid HIV test.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- U.S. Department of Health and Human Services (HHS) Secretary Tommy G. Thompson has announced that the U.S. Food and Drug Administration has approved a new rapid HIV diagnostic test kit that provides...

New method allows mass production of dendritic cells.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Large-scale production of dendritic cells is possible through the use of a cell selector followed by culture in a sterile-bag system, according to...

Transmission of ChimeriVax-DEN2 virus by vector mosquitoes is unlikely.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Study results indicate that the live virus contained in the ChimeriVax-DEN2 vaccine (Acambis, Inc.) has limited ability to infect and replicate in Aedes aegypti and Ae. albopictus mosquitoes. "The...

New data confirm the impact of once-per-cycle pegfilgrastim for neutropenia.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Data presented for the first time in Europe, at the 27th European Society of Medical Oncology (ESMO) Congress confirm that Neulasta (pegfilgrastim) has the potential to improve the management of...

Study: Fosrenol reduces hypercalcemia risk in end stage renal disease.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- AnorMED, Inc., (AOM) announced that Fosrenol (lanthanum carbonate), a new phosphate binder for use in dialysis patients, licensed to Shire Pharmaceuticals Group has shown to be effective in reducing...

Two phase II trials to evaluate efficacy of HDAC inhibitor SAHA.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Aton Pharma, Inc., announced that it has initiated a single-agent phase II clinical study of its lead product candidate, SAHA, in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL)....

New report calls for protecting at-risk civilians from anthrax.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- A panel of leading bioterrorism experts warned that the United States still lacks an articulated preparedness plan for immediate immunizations of at-risk civilians, a strategic anthrax vaccine...

Schering-Plough settles royalty payment arbitrations.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Schering-Plough Corp. (SGP) announced that it has settled its arbitrations with Biogen, Inc., over royalties on U.S. sales of Schering-Plough's alpha interferon products. As part of the settlement,...

Pharmaceutical group identifies new class of CpG oligonucleotides.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Coley Pharmaceutical Group, Inc., announced the identification of a novel class of its proprietary CpG oligo drug candidates, termed "C-Class" oligos. One member of this class, CpG 10101, strongly...

Surgeons perform first Zeus robotics system-assisted gastric bypass.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Although a casual observer in the operating room at Cedars-Sinai Medical Center on October 8, 2002, could have been pardoned for initially believing that the surgeon was playing high-tech video games,...

CryoLife reports third quarter and 9-month results.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- CryoLife, Inc., (CRY), a tissue-processing and medical device company, reported financial results for the third quarter and 9-month period ended September 30, 2002. Revenues for the third quarter...

BMP-7 may prevent bone and vascular complications.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Curis, Inc., (CRIS) announced its proprietary compound, BMP-7, has shown effectiveness for the prevention of several serious complications of chronic kidney disease in animal models of these disorders....

Thuris enters feasibility collaboration to test RapidAging.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Thuris and D-Pharm, Ltd., announced the initiation of a joint feasibility project designed to evaluate the therapeutic activity of D-Pharm's proprietary compounds with Thuris' RapidAging animal models....

Prometheus Laboratories obtains license to patent for pharmacogenetic test.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Prometheus Laboratories, Inc., announced that it has signed a coexclusive sublicense agreement with DNA Sciences, Inc., to a patent allowing for the identification of two gene forms, or alleles, that...

Neurogenetics, Inc., extends gene-discovery research agreement.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Neurogenetics, Inc., a privately held biopharmaceutical company, and Eisai Co., Ltd., announced the signing of a research agreement that will focus on the discovery of genes responsible for late-onset...

Sulfonamide derivative counters angiogenesis with integrin blockade.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - A new sulfonamide derivative, E7820, can inhibit neovascular signaling by blocking endothelial adhesion molecules, scientists at Tsukuba Research Laboratories...

Analysis: Company hopes to find growth in depression market with duloxetine.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Decision Resources, Inc., forecasts that Eli Lilly's new serotonin norepinephrine reuptake inhibitor (SNRI), duloxetine, will be the most promising drug to be launched between 2001-201. Duloxetine...

Company adds new cardiology medication to its product line.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Faulding Pharmaceutical Co. announced it will begin selling Amiodarone hydrochloride injection I.V. in the United States. "Amiodarone is one of a number of drugs we offer in our cardiology line of...

Dr. Barbara Seliger named to scientific advisory board.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX) announced that Professor Dr. Barbara Seliger has joined the company's scientific advisory board. Seliger is professor of immunology and pathophysiology at the Johannes...

Myriad Genetics enters strategic licensing agreement.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Myriad Genetics, Inc., (MYGN) and Genetic Technologies, Ltd., (GNTLF), announced the signing of a strategic alliance under which they will cross-license certain technologies related to the...

MediGene, Evotec, join forces to found new company.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- MediGene, AG, (MDG) and Evotec OAI, AG, (EVT) will become cofounders of the new company, "Genovation," emerging from the planned spin-off of MediGene's cardiological drug discovery program. In mid...

Study highlights potential of adult stem cells in tissue engineering.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Genzyme Biosurgery (GZBX), a division of Genzyme Corp., announced the publication of a research paper that casts new light on the nature of adult stem cells. Scientists in Genzyme's stem cell...

FDA approves nicotine lozenge.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Smokers trying to quit will soon be able to try a nicotine-containing lozenge to help reduce their cigarette cravings. The Food and Drug Administration approved GlaxoSmithKline's Commit lozenge for...

Chemotherapy well tolerated after yttrium-90 ibritumomab tiuxetan treatment.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Mayo Clinic hematologists report that in patients with relapsed B-cell non-Hodgkin lymphoma, chemotherapy or autologous stem cell transplantation after yttrium-90 ibritumomab tiuxetan treatment is...

Medix Biochemica licenses CEA antibody technology.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Immunomedics, Inc., (IMMU) announced that Medix Biochemica of Kauniainen, Finland, entered into a nonexclusive license agreement under Immunomedics' portfolio of carcinoembryonic antigen (CEA) patents....

Incara closes sale of liver cell program.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Incara Pharmaceuticals Corp. (INCR) announced that its wholly owned subsidiary, Incara Cell Technologies, Inc., has completed the sale of substantially all of the assets and certain related liabilities...

Merck KGaA enters $61 million international drug licensing agreement.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Merck KGaA and Kos Pharmaceuticals, Inc., (KOSP) announced a manufacturing and licensing agreement for Niaspan and Advicor, two products internally developed by Kos for the treatment of cholesterol...

Pharmacopeia enters new research collaboration.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Pharmacopeia, Inc., (PCOP) and Kowa Co., Ltd., announced that they have entered into a research collaboration focused on inflammation. The companies will work together to identify promising small...

Company wins patent to protect lead compound, NC381.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Lorus Therapeutics, Inc., announced that its subsidiary, NuChem Pharmaceuticals Inc., has received notice from the United States Patent and Trademark Office of the allowance of a patent that protects...

Company wins exclusive use of fluorescence detection technology.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Lumiphore, Inc., announced that it has been granted an exclusive license to two patents covering fluorescence detection technology using lanthanide complexes developed at the University of California,...

Company results for 2002 third quarter and 9-month period.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- MedImmune, Inc., (MEDI) announced that total revenues increased 53% to $73 million in the 2002 third quarter and 43% to $466 million in the first 9 months of the year. Worldwide sales of Synagis,...

Phase III study shows Synagis reduces RSV hospitalization.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- MedImmune, Inc., (MEDI) announced data from a large, multinational phase III clinical study indicating that Synagis (palivizumab) was safe and effective in preventing RSV-related hospitalizations in...

Court upholds Merck's patent for osteoporosis drug.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Merck & Co.'s patent for the osteoporosis drug Fosamax was upheld in federal court, the company said November 4, 2002. The decision by the U.S. District Court in Wilmington, Delaware, means Merck's...

California company licenses DNA sample processing technology.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- MicroFluidic Systems, Inc., (MFSI), a privately held company, of Pleasanton, California, has secured an exclusive license to U.S. patent no. 6,100,084, entitled "Micro-sonicator for Spore Lysis," from...

Company reports third quarter 2002 revenues of $95.8 million.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Millennium Pharmaceuticals, Inc., (MLNM) reported consolidated financial results for the 3 and 9 months ended September 30, 2002. Prior year comparisons do not include financial results for COR...

Bioanalytical measurement systems supplier reports third quarter results.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Molecular Devices Corp. (MDCC) announced that its revenues and earnings per share for the quarter ended September 30, 2002, were within management's previously stated guidance and consensus analyst...

MorphoSys updates guidance, terminates merger talks.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- MorphoSys, AG, (MOR), a Munich-based biotechnology company, announced that it has terminated merger talks with British Biotech, plc, (BBYIO). MorphoSys also updated its guidance regarding strategic...

Company prices public offering of common stock.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- NPS Pharmaceuticals, Inc., (NPSP) announced on October 25, 2002, that it has priced its public offering of 4,000,000 shares of its common stock at $23.95 per share. The company offered all of the...

Company provides corporate update, reports third quarter results.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- NPS Pharmaceuticals, Inc., (NPSP) provided an update of recent corporate activities and reported its operating results for the third quarter ended September 30, 2002. NPS announced that it has...

Stephen R. Parrish named vice president, manufacturing.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- NPS Pharmaceuticals, Inc., (NPSP) announced the appointment of Stephen R. Parrish as vice president, manufacturing. Parrish will oversee manufacturing affairs related to the company's proprietary...

Company's third quarter results exceed expectations.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Nabi Biopharmaceuticals (NABI) announced its financial results for the third quarter and 9 months ended September 28, 2002. Nabi Biopharmaceuticals reported net income of $0.8 million in the third...

International distribution agreements inked for Nabi-HB, hepatitis B antibody product.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Nabi Biopharmaceuticals (NABI) announced the signing of two international distribution agreements for Nabi-HB [hepatitis B immune globulin (human)] with Biotech Medical Corp. of Malaysia and Innovative...

Patent portfolio licensed from Lawrence Berkeley National Laboratories.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Nanosys, Inc., announced the signing of an exclusive field-of-use license agreement for a broad set of nanotechnology patents from Professor Paul Alivisatos at the Lawrence Berkeley National Laboratory....

Phase I trial data for neolipid anticancer agent LEM presented.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- NeoPharm, Inc., (NEOL) and its collaborators unveiled new preliminary clinical data from the company's phase I study of Liposome Encapsulated Mitoxantrone (LEM) in patients with advanced cancers at the...

NASDAQ approves Satraplatin developer's listing on Small-Cap Market.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- NeoTherapeutics, Inc., (NEOT) announced that the company has met all requirements for listing on the NASDAQ Small-Cap Market and that NASDAQ has approved the company's Small-Cap Market application. ...

Company gets IND for phase II trials with NCX 4016.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- NicOx, S.A., (NICOX) announced that its investigational new drug application (IND) has been accepted by the U.S. Food and Drug Administration (FDA) for the phase II clinical testing of NCX 4016, its...

Genome Institute of Singapore enters research collaboration.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- NuGEN Technologies, Inc., announced it has entered into a research collaboration with the Genome Institute of Singapore (GIS), an internationally renowned research center unifying genomic/computational...

Ferring and Johnson & Johnson join in a research collaboration.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Ferring announced that it will collaborate with Ortho-McNeil Pharmaceuticals,Inc., (Ortho-McNeil) and Ortho-McNeil's research affiliate, Johnson & Johnson Pharmaceutical Research & Development, LLC,...

FDA approves levofloxacin for hospital-acquired infection.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration (FDA) has approved Levaquin (levofloxacin) tablets/injection and Levaquin (levofloxacin in 5% dextrose) Injection 750 mg for the treatment of nosocomial pneumonia....

Company reports third quarter 2002 EPS growth of 50% to $0.33.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- PPD, Inc., (PPDI) reported that for its third quarter ended September 30, 2002, net revenue, excluding reimbursable out-of-pockets of $11.3 million, was $146 million, an increase of 35% over third...

NCI awards grant to develop diagnostic test for pancreatic cancer.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Panacea Pharmaceuticals, Inc., announced that it has been awarded a phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health...

Biotech outsourcing company reports first quarter financial results.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Parexel International Corp. (PRXL) announced that for the first quarter ended September 30, 2002, consolidated service revenue was $119.4 million compared with $101.8 million in the prior-year period, a...

Pharmaceutical company secures $22.1 million in series B financing.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Peninsula Pharmaceuticals, Inc., a pharmaceutical development company focused on developing and licensing clinical stage pharmaceutical products, announced that it has closed its Series B round of...

University of Kentucky researchers testing possible vaccine.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- University of Kentucky researchers are part of a national team testing a possible vaccine for a common type of adult diabetes. The vaccine, if successful, could eliminate or decrease the need for...

Pharmaceutical announces strong third-quarter 2002 results.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Pfizer, Inc., reported that third-quarter net income increased by 12% to $2.452 billion and diluted earnings per share (EPS) increased by 15% to $0.39, both from continuing operations excluding certain...

Company reports third-quarter sales and earnings.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Pharmaceutical Resources, Inc., (PRX) reported total revenues of $100.2 million for the third quarter ended September 30, 2002, net income of $19.6 million, and diluted earnings per share of $0.59,...

Genpharm wins FDA tentative approval for omeprazole.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Pharmaceutical Resources, Inc., (PRX) announced that the FDA granted tentative approval to Genpharm for omeprazole. The product has now cleared all scientific and regulatory requirements for a...

New class of compounds found for the treatment of drug-resistant HIV/AIDS.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Pharmacor announced the discovery of a new class of drug-like compounds in its battle against drug-resistant HIV. The exceptional characteristic of these compounds is that they are significantly...

Dexanabinol maker adopts stockholder rights plan and bylaw revisions.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Pharmos Corp. (PARS) announced that its board of directors approved the adoption of a stockholder rights plan as well as certain revisions to its bylaws, Under the terms of the plan, Pharmos is...

Investigational new drug application filed for phase III study of dexanabinol.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Pharmos Corp. (PARS) announced the submission to the FDA of an investigational new drug (IND) application to begin U.S. patient enrollment in its pivotal phase III trial of dexanabinol for the treatment...

Company reports on clinical trials.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Praxis Pharmaceuticals, Inc., reported that Pharmaxis Pty, Ltd., is completing phase II clinical trials as reported in the recently filed Praxis Pharmaceuticals 10k. Pharmaxis is a research and...

Canadian biotech company obtains issuance of cell packaging patent.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Prescient NeuroPharma, Inc., (PRE) Anthony J. Giovinazzo, president and CEO, announced that PRE received a notice of issuance from the U.S. Patent Office for a patent titled: Methods For Producing and...

Prescient announces conclusion of bridge financing agreement.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Prescient NeuroPharma, Inc., (PRE) having obtained regulatory approval on October 8, 2002, announced the conclusion of a bridge financing agreement with its main investors: GeneChem Technologies Venture...

Biotech company establishes headquarters at Cleveland Clinic Foundation campus.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- The Cleveland Clinic Foundation and Quark Biotech, Inc., announced the establishment of Quark's headquarters and laboratories located in the center of the Clinic's campus. Quark has leased a...

CF Complete test launched; provides sequencing of cystic fibrosis gene.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Quest Diagnostics, Inc., (DGX), a provider of diagnostic testing, information and services, introduced its new CF Complete test at the 52nd annual meeting of The American Society of Human Genetics. ...

Quest Diagnostics reports increased revenues and earnings for third quarter 2002.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Quest Diagnostics, Inc., (DGX), a provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2002, net income increased to $87 million, or $0.87...

Safety data released from extension of phase II clinical trial of Secretin.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Repligen Corp. (RGEN) announced results from an open label "Extension Study" of its phase II clinical trial of RG1068, human synthetic secretin, in children with autism, to collect additional...

European Union's CPMP recommends Approval of Caelyx.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Schering-Plough Corp. (SGP) reported that the European Union's (E.U.) Committee for Proprietary Medicinal Products (CPMP) of the European Agency for the Evaluation of Medicinal Products (EMEA) has...

John J. Roberts named to board of directors.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Sicor, Inc., (SCRI) announced the election of John J. Roberts to the company's board of directors and to the board's audit committee. Roberts spent more than 35 years with the accounting firm of...

HspE7 partner reports third quarter 2002 financial results.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Stressgen Biotechnologies Corp. (SSB) reported financial results for the quarter and 9 months ended September 30, 2002. All amounts, unless specified otherwise, are in Canadian dollars. "This...

Company continues expansion of global stem cell network.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- ThermoGenesis Corp. (KOOL) announced that the company received an order for a second BioArchive System from Healthbanks in Taipei, Taiwan. The BioArchive System is used as a critical enabling...

Pharma company enters collaboration with lay advocacy group for PXE.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Transgenomic, Inc., (TBIO) and nonprofit organization PXE International announced that they have entered into a collaboration to develop a diagnostic test for the genetic condition, pseudoxanthoma...

Enzyme replacement therapy holds promise for kids with rare genetic disorder.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- A clinical study led by the University of North Carolina medical center indicates that a novel enzyme replacement therapy benefited pediatric patients with Hunter syndrome, a rare genetic disorder for...

FDA accepts Coviracil NDA for the treatment of HIV.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Triangle Pharmaceuticals, Inc., (VIRS) announced that the U.S. Food and Drug Administration (FDA) has notified the company that its new drug application (NDA) for marketing approval of Coviracil for the...

Company appeals delisting notification from NASDAQ.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Vion Pharmaceuticals, Inc., (VION) announced that it will appeal Nasdaq's determination to delist Vion's common stock from the NASDAQ National Market by requesting a hearing before a NASDAQ Listing...

Surveillance Data enters partnership to create new HIV market data products.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- ViroLogic, Inc., (VLGC) and Surveillance Data, Inc., (SDI), announced that the companies have signed an agreement to create a new line of HIV market research products based on data collected through...

FDA denies pediatric exclusivity for Cordarone I.V.
December 4, 2002... 2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Wyeth (WYE) announced that the United States Food and Drug Administration (FDA) has denied Wyeth's antiarrhythmic drug Cordarone I.V. (amiodarone hydrochloride) 6 months of market exclusivity under the...